Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - ELEC LB - 1. AU - Reveille, JD TI - Spondyloarthritis PB - American College of Rheumatology PY - 2013 UR - www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Spondyloarthritis M1 - 28 July 2016 ER - TY - ELEC LB - 2. AU - Arthritis Foundation TI - What is Psoriatic Arthritis? PB - Arthritis Foundation National Office UR - www.arthritis.org/about-arthritis/types/psoriatic-arthritis/what-is-psoriatic-arthritis.php M1 - 7 July 2016 ER - TY - ELEC LB - 3. AU - Emery, P AU - Ash, Z TI - Psoriatic Arthritis PB - American College of Rheumatology PY - 2013 UR - www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Psoriatic-Arthritis M1 - 28 July 2016 ER - TY - ELEC LB - 4. AU - Shiel, WC TI - Psoriatic Arthritis PY - 2015 UR - www.medicinenet.com/psoriatic_arthritis/article.htm M1 - 25 November 2015 ER - TY - JOUR LB - 5. AU - Gladman, DD AU - Shuckett, R AU - Russell, ML AU - Thorne, JC AU - Schachter, RK TI - Psoriatic arthritis (PSA) – an analysis of 220 patients J2 - Q J Med PY - 1987 VL - 62 SP - 127 EP - 141 ER - TY - JOUR LB - 6. AU - Torre Alonso, JC AU - Rodriguez Perez, A AU - Arribas Castrillo, JM AU - Ballina Garcia, J AU - Riestra Noriega, JL AU - Lopez Larrea, C TI - Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients J2 - Br J Rheumatol PY - 1991 VL - 30 SP - 245 EP - 250 UR - https://doi.org/10.1093/rheumatology/30.4.245 ER - TY - JOUR LB - 7. AU - Galadari, H AU - Fuchs, B AU - Lebwohl, M TI - Newly available treatments for psoriatic arthritis and their impact on skin psoriasis J2 - Int J Dermatol PY - 2003 VL - 42 SP - 231 EP - 237 UR - https://doi.org/10.1046/j.1365-4362.2003.01449.x ER - TY - JOUR LB - 8. AU - Ruderman, EM TI - Evaluation and management of psoriatic arthritis: the role of biologic therapy J2 - J Am Acad Dermatol PY - 2003 VL - 49 IS - Suppl. 2 SP - 125 EP - 132 UR - https://doi.org/10.1016/S0190-9622(03)01145-9 ER - TY - JOUR LB - 9. AU - Michelsen, B AU - Fiane, R AU - Diamantopoulos, AP AU - Soldal, DM AU - Hansen, IJ AU - Sokka, T TI - A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis J2 - PLOS ONE PY - 2015 VL - 10 SP - e0123582 UR - https://doi.org/10.1371/journal.pone.0123582 ER - TY - JOUR LB - 10. AU - Kavanaugh, A AU - Mease, PJ AU - Purcaru, O AU - van der Heijde, D TI - High economic burden of moderate to severe psoriatic arthritis on paid work and household productivity: baseline results from the RAPID-PsA study (poster SAT0275) J2 - Ann Rheum Dis PY - 2013 VL - 72 IS - Suppl. 3 SP - 676 UR - https://doi.org/10.1136/annrheumdis-2013-eular.2000 ER - TY - JOUR LB - 11. AU - Mease, P AU - Goffe, BS TI - Diagnosis and treatment of psoriatic arthritis J2 - J Am Acad Dermatol PY - 2005 VL - 52 SP - 1 EP - 19 UR - https://doi.org/10.1016/j.jaad.2004.06.013 ER - TY - JOUR LB - 12. AU - Wong, K AU - Gladman, DD AU - Husted, J AU - Long, JA AU - Farewell, VT TI - Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death J2 - Arthritis Rheum PY - 1997 VL - 40 SP - 1868 EP - 1872 UR - https://doi.org/10.1002/1529-0131(199710)40:10<1868::AID-ART21>3.0.CO;2-W ER - TY - JOUR LB - 13. AU - Gladman, DD AU - Farewell, VT AU - Wong, K AU - Husted, J TI - Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death J2 - Arthritis Rheum PY - 1998 VL - 41 SP - 1103 EP - 1110 UR - https://doi.org/10.1002/1529-0131(199806)41:6<1103::AID-ART18>3.0.CO;2-N ER - TY - JOUR LB - 14. AU - Ali, Y AU - Tom, BD AU - Schentag, CT AU - Farewell, VT AU - Gladman, DD TI - Improved survival in psoriatic arthritis with calendar time J2 - Arthritis Rheum PY - 2007 VL - 56 SP - 2708 EP - 2714 UR - https://doi.org/10.1002/art.22800 ER - TY - JOUR LB - 15. AU - Helliwell, PS AU - Taylor, WJ TI - Classification and diagnostic criteria for psoriatic arthritis J2 - Ann Rheum Dis PY - 2005 VL - 64 IS - Suppl. 2 SP - ii3 EP - ii8 UR - https://doi.org/10.1136/ard.2004.032318 ER - TY - JOUR LB - 16. AU - Moll, JM AU - Wright, V TI - Psoriatic arthritis J2 - Semin Arthritis Rheum PY - 1973 VL - 3 SP - 55 EP - 78 UR - https://doi.org/10.1016/0049-0172(73)90035-8 ER - TY - JOUR LB - 17. AU - Taylor, W AU - Gladman, D AU - Helliwell, P AU - Marchesoni, A AU - Mease, P AU - Mielants, H TI - Classification criteria for psoriatic arthritis: development of new criteria from a large international study J2 - Arthritis Rheum PY - 2006 VL - 54 SP - 2665 EP - 2673 UR - https://doi.org/10.1002/art.21972 ER - TY - JOUR LB - 18. AU - Gladman, DD AU - Antoni, C AU - Mease, P AU - Clegg, DO AU - Nash, P TI - Psoriatic arthritis: epidemiology, clinical features, course, and outcome J2 - Ann Rheum Dis PY - 2005 VL - 64 IS - Suppl. 2 SP - ii14 EP - ii17 UR - https://doi.org/10.1136/ard.2004.032482 ER - TY - ELEC LB - 19. AU - Salisbury NHS Foundation Trust TI - Referral Pathway for Psoriatic Arthritis PB - Salisbury NHS Foundation Trust UR - www.icid.salisbury.nhs.uk/ClinicalManagement/Rheumatology/Pages/PsA.aspx M1 - 7 July 2016 ER - TY - JOUR LB - 20. AU - Bowcock, AM TI - Understanding the pathogenesis of psoriasis, psoriatic arthritis, and autoimmunity via a fusion of molecular genetics and immunology J2 - Immunol Res PY - 2005 VL - 32 SP - 45 EP - 56 UR - https://doi.org/10.1385/IR:32:1-3:045 ER - TY - JOUR LB - 21. AU - Leung, YY AU - Tam, LS AU - Kun, EW AU - Li, EK TI - Psoriatic arthritis as a distinct disease entity J2 - J Postgrad Med PY - 2007 VL - 53 SP - 63 EP - 71 UR - https://doi.org/10.4103/0022-3859.30334 ER - TY - JOUR LB - 22. AU - Ritchlin, CT AU - Qureshi, AA AU - de Vlam, K AU - Pitzalis, C AU - Helliwell, PS AU - Mease, PJ TI - Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008 J2 - J Rheumatol PY - 2010 VL - 37 SP - 462 EP - 467 UR - https://doi.org/10.3899/jrheum.090957 ER - TY - ELEC LB - 23. AU - GRAPPA TI - Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) PB - GRAPPA PY - 2016 UR - www.grappanetwork.org/ M1 - 12 July 2016 ER - TY - JOUR LB - 24. AU - Felson, DT AU - Anderson, JJ AU - Boers, M AU - Bombardier, C AU - Furst, D AU - Goldsmith, C TI - American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis J2 - Arthritis Rheum PY - 1995 VL - 38 SP - 727 EP - 735 UR - https://doi.org/10.1002/art.1780380602 ER - TY - JOUR LB - 25. AU - Mease, PJ AU - Antoni, CE AU - Gladman, DD AU - Taylor, WJ TI - Psoriatic arthritis assessment tools in clinical trials J2 - Ann Rheum Dis PY - 2005 VL - 64 IS - Suppl. 2 SP - ii49 EP - ii54 UR - https://doi.org/10.1136/ard.2004.034165 ER - TY - JOUR LB - 26. AU - Wong, PC AU - Leung, YY AU - Li, EK AU - Tam, LS TI - Measuring disease activity in psoriatic arthritis J2 - Int J Rheumatol PY - 2012 VL - 2012 SP - 839425 UR - https://doi.org/10.1155/2012/839425 ER - TY - ELEC LB - 27. AU - Chang, CA AU - Gottlieb, AB AU - Lizzul, PF TI - Management of Psoriatic Arthritis from the View of the Dermatologist: Assessment of PsA PB - Medscape PY - 2011 UR - www.medscape.org/viewarticle/749147_2 M1 - 6 July 2016 ER - TY - JOUR LB - 28. AU - Kavanaugh, A AU - Cassell, S TI - The assessment of disease activity and outcomes in psoriatic arthritis J2 - Clin Exp Rheumatol PY - 2005 VL - 23 IS - Suppl. 5 SP - 142 EP - 147 ER - TY - JOUR LB - 29. AU - Gossec, L AU - Smolen, JS AU - Ramiro, S AU - de Wit, M AU - Cutolo, M AU - Dougados, M TI - European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update J2 - Ann Rheum Dis PY - 2016 VL - 75 SP - 499 EP - 510 UR - https://doi.org/10.1136/annrheumdis-2015-208337 ER - TY - JOUR LB - 30. AU - Mease, PJ TI - Psoriatic arthritis: update on pathophysiology, assessment and management J2 - Ann Rheum Dis PY - 2011 VL - 70 IS - Suppl. 1 SP - i77 EP - i84 UR - https://doi.org/10.1136/ard.2010.140582 ER - TY - JOUR LB - 31. AU - Coates, LC AU - Tillett, W AU - Chandler, D AU - Helliwell, PS AU - Korendowych, E AU - Kyle, S TI - The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics J2 - Rheumatology PY - 2013 VL - 52 SP - 1754 EP - 1757 UR - https://doi.org/10.1093/rheumatology/ket187 ER - TY - JOUR LB - 32. AU - Haberhauer, G AU - Strehblow, C AU - Fasching, P TI - Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis J2 - Wien Med Wochenschr PY - 2010 VL - 160 SP - 220 EP - 224 UR - https://doi.org/10.1007/s10354-010-0795-0 ER - TY - JOUR LB - 33. AU - Rodgers, M AU - Epstein, D AU - Bojke, L AU - Yang, H AU - Craig, D AU - Fonseca, T TI - Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluation J2 - Health Technol Assess PY - 2011 VL - 15 IS - 10 UR - https://doi.org/10.3310/hta15100 ER - TY - JOUR LB - 34. AU - Yang, H AU - Craig, D AU - Epstein, D AU - Bojke, L AU - Light, K AU - Bruce, IN TI - Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal J2 - PharmacoEconomics PY - 2012 VL - 30 SP - 257 EP - 270 UR - https://doi.org/10.2165/11595920-000000000-00000 ER - TY - JOUR LB - 35. AU - O’Connor, J AU - Rice, S AU - Smith, A AU - Rodgers, M AU - Lopez, RR AU - Craig, D TI - The clinical and cost effectiveness of ustekinumab for the treatment of psoriatic arthritis: a critique of the evidence J2 - PharmacoEconomics PY - 2016 VL - 34 SP - 337 UR - https://doi.org/10.1007/s40273-015-0350-3 ER - TY - JOUR LB - 36. AU - Cawson, MR AU - Mitchell, SA AU - Knight, C AU - Wildey, H AU - Spurden, D AU - Bird, A TI - Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active psoriatic arthritis J2 - BMC Musculoskelet Disord PY - 2014 VL - 15 SP - 26 UR - https://doi.org/10.1186/1471-2474-15-26 ER - TY - JOUR LB - 37. AU - Ungprasert, P AU - Thongprayoon, C AU - Davis, JM TI - Indirect comparisons of the efficacy of biological agents in patients with psoriatic arthritis with an inadequate response to traditional disease-modifying anti-rheumatic drugs or to non-steroidal anti-inflammatory drugs: a meta-analysis J2 - Semin Arthritis Rheum PY - 2016 VL - 45 SP - 428 EP - 438 UR - https://doi.org/10.1016/j.semarthrit.2015.09.004 ER - TY - JOUR LB - 38. AU - Migliore, A AU - Bizzi, E AU - Broccoli, S AU - Lagana, B TI - Indirect comparison of etanercept, infliximab, and adalimumab for psoriatic arthritis: mixed treatment comparison using placebo as common comparator J2 - Clin Rheumatol PY - 2012 VL - 31 SP - 133 EP - 137 UR - https://doi.org/10.1007/s10067-011-1790-6 ER - TY - JOUR LB - 39. AU - Ramiro, S AU - Smolen, JS AU - Landewe, R AU - van der Heijde, D AU - Dougados, M AU - Emery, P TI - Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis J2 - Ann Rheum Dis PY - 2016 VL - 75 SP - 490 EP - 498 UR - https://doi.org/10.1136/annrheumdis-2015-208466 ER - TY - JOUR LB - 40. AU - Corbett, MS AU - Higgins, JP AU - Woolacott, NF TI - Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool J2 - Res Synth Methods PY - 2014 VL - 5 SP - 79 EP - 85 UR - https://doi.org/10.1002/jrsm.1090 ER - TY - JOUR LB - 41. AU - Maneiro, JR AU - Souto, A AU - Salgado, E AU - Mera, A AU - Gomez-Reino, JJ TI - Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis J2 - RMD Open PY - 2015 VL - 1 SP - e000017 UR - https://doi.org/10.1136/rmdopen-2014-000017 ER - TY - JOUR LB - 42. AU - Sterry, W AU - Ortonne, JP AU - Kirkham, B AU - Brocq, O AU - Robertson, D AU - Pedersen, RD TI - Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial J2 - BMJ PY - 2010 VL - 340 SP - c147 UR - https://doi.org/10.1136/bmj.c147 ER - TY - JOUR LB - 43. AU - Schett, G AU - Wollenhaupt, J AU - Papp, K AU - Joos, R AU - Rodrigues, JF AU - Vessey, AR TI - Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study J2 - Arthritis Rheum PY - 2012 VL - 64 SP - 3156 EP - 3167 UR - https://doi.org/10.1002/art.34627 ER - TY - JOUR LB - 44. AU - Torii, H AU - Nakagawa, H AU - Japanese Infliximab Study investigators TI - Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial J2 - J Dermatol Sci PY - 2010 VL - 59 SP - 40 EP - 49 UR - https://doi.org/10.1016/j.jdermsci.2010.04.014 ER - TY - JOUR LB - 45. AU - Baranauskaite, A AU - Raffayová, H AU - Kungurov, NV AU - Kubanova, A AU - Venalis, A AU - Helmle, L TI - Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study J2 - Ann Rheum Dis PY - 2012 VL - 71 SP - 541 EP - 548 UR - https://doi.org/10.1136/ard.2011.152223 ER - TY - JOUR LB - 46. AU - Mease, PJ AU - McInnes, IB AU - Kirkham, B AU - Kavanaugh, A AU - Rahman, P AU - van der Heijde, D TI - Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis J2 - N Engl J Med PY - 2015 VL - 373 SP - 1329 EP - 1339 UR - https://doi.org/10.1056/NEJMoa1412679 ER - TY - JOUR LB - 47. AU - Mease, PJ AU - Fleischmann, R AU - Deodhar, AA AU - Wollenhaupt, J AU - Khraishi, M AU - Kielar, D TI - Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA) J2 - Ann Rheum Dis PY - 2014 VL - 73 SP - 48 EP - 55 UR - https://doi.org/10.1136/annrheumdis-2013-203696 ER - TY - JOUR LB - 48. AU - McInnes, IB AU - Mease, PJ AU - Kirkham, B AU - Kavanaugh, A AU - Ritchlin, CT AU - Rahman, P TI - Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial J2 - Lancet PY - 2015 VL - 386 SP - 1137 EP - 1146 UR - https://doi.org/10.1016/S0140-6736(15)61134-5 ER - TY - JOUR LB - 49. AU - Gottlieb, AB AU - Langley, RG AU - Philipp, S AU - Sigurgeirsson, B AU - Blauvelt, A AU - Martin, R TI - Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials J2 - J Drugs Dermatol PY - 2015 VL - 14 SP - 821 EP - 833 ER - TY - JOUR LB - 50. AU - Kavanaugh, A AU - McInnes, I AU - Mease, P AU - Krueger, GG AU - Gladman, D AU - Gomez-Reino, J TI - Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study J2 - Arthritis Rheum PY - 2009 VL - 60 SP - 976 EP - 986 UR - https://doi.org/10.1002/art.24403 ER - TY - JOUR LB - 51. AU - Antoni, CE AU - Kavanaugh, A AU - Kirkham, B AU - Tutuncu, Z AU - Burmester, GR AU - Schneider, U TI - Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT) J2 - Arthritis Rheum PY - 2005 VL - 52 SP - 1227 EP - 1236 UR - https://doi.org/10.1002/art.20967 ER - TY - JOUR LB - 52. AU - Antoni, C AU - Krueger, GG AU - de Vlam, K AU - Birbara, C AU - Beutler, A AU - Guzzo, C TI - Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial J2 - Ann Rheum Dis PY - 2005 VL - 64 SP - 1150 EP - 1157 UR - https://doi.org/10.1136/ard.2004.032268 ER - TY - JOUR LB - 53. AU - Mease, PJ AU - Goffe, BS AU - Metz, J AU - VanderStoep, A AU - Finck, B AU - Burge, DJ TI - Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial J2 - Lancet PY - 2000 VL - 356 SP - 385 EP - 390 UR - https://doi.org/10.1016/S0140-6736(00)02530-7 ER - TY - JOUR LB - 54. AU - Mease, PJ AU - Kivitz, AJ AU - Burch, FX AU - Siegel, EL AU - Cohen, SB AU - Ory, P TI - Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression J2 - Arthritis Rheum PY - 2004 VL - 50 SP - 2264 EP - 2272 UR - https://doi.org/10.1002/art.20335 ER - TY - JOUR LB - 55. AU - Mease, PJ AU - Gladman, DD AU - Ritchlin, CT AU - Ruderman, EM AU - Steinfeld, SD AU - Choy, EH TI - Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial J2 - Arthritis Rheum PY - 2005 VL - 52 SP - 3279 EP - 3289 UR - https://doi.org/10.1002/art.21306 ER - TY - JOUR LB - 56. AU - Genovese, MC AU - Mease, PJ AU - Thomson, GT AU - Kivitz, AJ AU - Perdok, RJ AU - Weinberg, MA TI - Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy J2 - J Rheumatol PY - 2007 VL - 34 SP - 1040 EP - 1050 ER - TY - JOUR LB - 57. AU - Mease, PJ AU - van der Heijde, D AU - Ritchlin, CT AU - Cuchacovich, R AU - Shuler, CL AU - Lee, CH TI - A randomized, double-blind, active-and placebo-controlled phase 3 study of efficacy and safety of ixekizumab, adalimumab, and placebo therapy in patients naive to biologic disease modifying anti-rheumatic drugs with active psoriatic arthritis J2 - Arthritis Rheumatol PY - 2015 VL - 67 IS - Suppl. 10 SP - 977 ER - TY - JOUR LB - 58. AU - McInnes, IB AU - Kavanaugh, A AU - Gottlieb, AB AU - Puig, L AU - Rahman, P AU - Ritchlin, C TI - Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial J2 - Lancet PY - 2013 VL - 382 SP - 780 EP - 789 UR - https://doi.org/10.1016/S0140-6736(13)60594-2 ER - TY - JOUR LB - 59. AU - Ritchlin, C AU - Rahman, P AU - Kavanaugh, A AU - McInnes, IB AU - Puig, L AU - Li, S TI - Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial J2 - Ann Rheum Dis PY - 2014 VL - 73 SP - 990 EP - 999 UR - https://doi.org/10.1136/annrheumdis-2013-204655 ER - TY - JOUR LB - 60. AU - Kavanaugh, A AU - Mease, PJ AU - Gomez-Reino, JJ AU - Adebajo, AO AU - Wollenhaupt, J AU - Gladman, DD TI - Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor J2 - Ann Rheum Dis PY - 2014 VL - 73 SP - 1020 EP - 1026 UR - https://doi.org/10.1136/annrheumdis-2013-205056 ER - TY - ELEC LB - 61. AU - National Institute for Health and Care Excellence (NICE) TI - Psoriatic Arthritis (Active) – Apremilast (Post DMARDs) [ID682] PB - NICE PY - 2015 UR - www.nice.org.uk/guidance/TA372/documents/psoriatic-arthritis-active-apremilast-post-dmards-id682-committee-papers-2 M1 - 19 May 2016 ER - TY - JOUR LB - 62. AU - Gottlieb, AB AU - Thaci, D AU - Blauvelt, A AU - Milutinovic, M AU - Mpofu, S TI - Secukinumab improves skin symptoms and physical functioning compared with ustekinumab in patients with moderate to severe psoriasis with concomitant psoriatic arthritis: subanalysis of a randomized, double blind, parallel-group, active comparator-controlled phase 3b trial J2 - Arthritis Rheumatol PY - 2015 VL - 67 IS - Suppl. 10 SP - 2853 ER - TY - JOUR LB - 63. AU - Thaçi, D AU - Blauvelt, A AU - Reich, K AU - Tsai, TF AU - Vanaclocha, F AU - Kingo, K TI - Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial J2 - J Am Acad Dermatol PY - 2015 VL - 73 SP - 400 EP - 409 UR - https://doi.org/10.1016/j.jaad.2015.05.013 ER - TY - JOUR LB - 64. AU - Atteno, M AU - Peluso, R AU - Costa, L AU - Padula, S AU - Iervolino, S AU - Caso, F TI - Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs J2 - Clin Rheumatol PY - 2010 VL - 29 SP - 399 EP - 403 UR - https://doi.org/10.1007/s10067-009-1340-7 ER - TY - BOOK LB - 65. AU - Corbett, M AU - Sideris, E AU - Palmer, S AU - Harden, M AU - Woolacott, N AU - Bojke, L TI - Evidence Review Group’s Report: Apremilast for Treating Active Psoriatic Arthritis CY - Southampton PB - National Institute for Health Research PY - 2015 ER - TY - BOOK LB - 66. AU - Craig, D AU - O’Connor, J AU - Rodgers, M AU - Rodriguez-Lopez, R AU - Smith, A AU - Woolacott, N TI - Evidence Review Group’s Report: Ustekinumab for Treating Active and Progressive Psoriatic Arthritis CY - Southampton PB - National Institute for Health Research PY - 2013 UR - www.journalslibrary.nihr.ac.uk/programmes/hta/125801/#/ Y2 - 19 May 2017 ER - TY - JOUR LB - 67. AU - Gottlieb, AB AU - Mease, PJ AU - Cuchacovich, RS AU - Shuler, CL AU - Lin, CY AU - Burge, RT TI - Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis J2 - Arthritis Rheumatol PY - 2015 VL - 67 IS - Suppl. 10 SP - 2145 ER - TY - JOUR LB - 68. AU - Gottlieb, AB AU - Sigurgeirsson, B AU - Blauvelt, A AU - Mpfofu, S AU - Martin, R AU - Papavassilis, C TI - Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis patients with psoriatic arthritis: a subanalysis of a phase 3, multicenter, double-blind, placebo-controlled study J2 - Arthritis Rheum PY - 2013 VL - 65 SP - S136 EP - S137 ER - TY - BOOK LB - 69. AU - European Medicines Agency TI - Assessment Report: Otezla CY - London PB - European Medicines Agency PY - 2014 ER - TY - BOOK LB - 70. AU - Yang, H AU - Epstein, D AU - Bojke, L AU - Craig, D AU - Light, K AU - Bruce, I TI - Evidence Review Group’s Report: Golimumab for the Treatment of Psoriatic Arthritis CY - Southampton PB - National Institute for Health Research PY - 2010 UR - www.journalslibrary.nihr.ac.uk/programmes/hta/0912001/#/ Y2 - 19 May 2017 ER - TY - ELEC LB - 71. AU - Novartis Pharmaceuticals TI - 24 Week Efficacy and 3-Year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis PY - 2013 UR - https://ClinicalTrials.gov/show/NCT01989468 M1 - 7 December 2015 ER - TY - ELEC LB - 72. AU - Novartis Pharmaceuticals TI - Efficacy at 24 Weeks with Long Term Safety, Tolerability and Efficacy up to 5 years of Secukinumab in Patients of Active Psoriatic Arthritis PY - 2012 UR - https://ClinicalTrials.gov/show/NCT01752634 M1 - 7 December 2015 ER - TY - ELEC LB - 73. AU - Novartis Pharmaceuticals TI - Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 years of Secukinumab in Active Psoriatic Arthritis PY - 2015 UR - https://ClinicalTrials.gov/show/NCT02404350 M1 - 7 December 2016 ER - TY - JOUR LB - 74. AU - Mease, P AU - Deodhar, A AU - Fleischmann, R AU - Wollenhaupt, J AU - Gladman, D AU - Leszczyński, P TI - Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure J2 - RMD Open PY - 2015 VL - 1 SP - e000119 UR - https://doi.org/10.1136/rmdopen-2015-000119 ER - TY - JOUR LB - 75. AU - Kavanaugh, A AU - McInnes, IB AU - Mease, P AU - Krueger, GG AU - Gladman, D AU - van der Heijde, D TI - Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study) J2 - Ann Rheum Dis PY - 2014 VL - 73 SP - 1689 EP - 1694 UR - https://doi.org/10.1136/annrheumdis-2013-204902 ER - TY - JOUR LB - 76. AU - Krueger, GG TI - Effects of golimumab on the dermatologic manifestations of psoriatic arthritis: 5-year results from the long-term extension of the randomized, placebo-controlled, GO-REVEAL study J2 - J Am Acad Dermatol PY - 2013 VL - 68 IS - Suppl. 1 SP - AB199 ER - TY - JOUR LB - 77. AU - Mease, PJ AU - Kivitz, AJ AU - Burch, FX AU - Siegel, EL AU - Cohen, SB AU - Ory, P TI - Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept J2 - J Rheumatol PY - 2006 VL - 33 SP - 712 EP - 721 ER - TY - JOUR LB - 78. AU - Mease, PJ AU - Ory, P AU - Sharp, JT AU - Ritchlin, CT AU - Van den Bosch, F AU - Wellborne, F TI - Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) J2 - Ann Rheum Dis PY - 2009 VL - 68 SP - 702 EP - 709 UR - https://doi.org/10.1136/ard.2008.092767 ER - TY - JOUR LB - 79. AU - Antoni, CE AU - Kavanaugh, A AU - van der Heijde, D AU - Beutler, A AU - Keenan, G AU - Zhou, B TI - Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT) J2 - J Rheumatol PY - 2008 VL - 35 SP - 869 EP - 876 ER - TY - JOUR LB - 80. AU - Kavanaugh, A AU - Puig, L AU - Gottlieb, AB AU - Ritchlin, C AU - Li, S AU - Wang, Y TI - Maintenance of clinical efficacy and radiographic benefit through 2 years of ustekinumab therapy in patients with active psoriatic arthritis: results from a randomized, placebo-controlled phase III trial J2 - Arthritis Care Res PY - 2015 VL - 67 SP - 1739 EP - 1749 UR - https://doi.org/10.1002/acr.22645 ER - TY - JOUR LB - 81. AU - Kavanaugh, A AU - Puig, L AU - Gottlieb, A AU - Ritchlin, C AU - Li, S AU - Wang, Y TI - Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 2-year results from a phase 3, multicenter, double-blind, placebo-controlled study J2 - Ann Rheum Dis PY - 2014 VL - 73 IS - Suppl. 2 SP - 737 EP - 738 UR - https://doi.org/10.1136/annrheumdis-2014-eular.2283 ER - TY - JOUR LB - 82. AU - Bird, P AU - Adebajo, A AU - Gladman, D AU - Kavanaugh, A AU - Mease, P AU - Gomez-Reino, J TI - Long-term (104-week) efficacy and safety profile of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results from a phase III, randomized, controlled trial and open-label extension (PALACE 1) J2 - Intern Med J PY - 2015 VL - 45 IS - Suppl. 2 SP - 39 EP - 40 ER - TY - JOUR LB - 83. AU - Saad, AA AU - Ashcroft, DM AU - Watson, KD AU - Hyrich, KL AU - Noyce, PR AU - Symmons, DPM TI - Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register J2 - Arthritis Res Ther PY - 2009 VL - 11 SP - R52 UR - https://doi.org/10.1186/ar2670 ER - TY - JOUR LB - 84. AU - Fagerli, K AU - Watson, K AU - Packham, J AU - Symmons, D AU - Hyrich, K TI - Predicting successful long-term treatment with tumour necrosis factor-alpha inhibitors in patients with psoriatic arthritis J2 - Arthritis Rheumatol PY - 2014 VL - 66 SP - S679 EP - SS80 ER - TY - JOUR LB - 85. AU - Kristensen, LE AU - Gulfe, A AU - Saxne, T AU - Geborek, P TI - Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register J2 - Ann Rheum Dis PY - 2008 VL - 67 SP - 364 EP - 369 UR - https://doi.org/10.1136/ard.2007.073544 ER - TY - JOUR LB - 86. AU - Simard, JF AU - Arkema, EV AU - Sundström, A AU - Geborek, P AU - Saxne, T AU - Baecklund, E TI - Ten years with biologics: to whom do data on effectiveness and safety apply? J2 - Rheumatology PY - 2011 VL - 50 SP - 204 EP - 213 UR - https://doi.org/10.1093/rheumatology/keq326 ER - TY - JOUR LB - 87. AU - Mease, PJ AU - Collier, DH AU - Saunders, KC AU - Li, G AU - Kremer, JM AU - Greenberg, JD TI - Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry J2 - RMD Open PY - 2015 VL - 1 SP - e000181 UR - https://doi.org/10.1136/rmdopen-2015-000181 ER - TY - JOUR LB - 88. AU - Glintborg, B AU - Østergaard, M AU - Dreyer, L AU - Krogh, NS AU - Tarp, U AU - Hansen, MS TI - Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry J2 - Arthritis Rheum PY - 2011 VL - 63 SP - 382 EP - 390 UR - https://doi.org/10.1002/art.30117 ER - TY - JOUR LB - 89. AU - Chen, JS AU - Makovey, J AU - Lassere, M AU - Buchbinder, R AU - March, LM TI - Comparative effectiveness of anti-tumor necrosis factor drugs on health-related quality of life among patients with inflammatory arthritis J2 - Arthritis Care Res PY - 2014 VL - 66 SP - 464 EP - 472 UR - https://doi.org/10.1002/acr.22151 ER - TY - JOUR LB - 90. AU - Fagerli, KM AU - Lie, E AU - van der Heijde, D AU - Heiberg, MS AU - Lexberg, AS AU - Rødevand, E TI - The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study J2 - Ann Rheum Dis PY - 2014 VL - 73 SP - 132 EP - 137 UR - https://doi.org/10.1136/annrheumdis-2012-202347 ER - TY - JOUR LB - 91. AU - Carmona, L AU - Gomez-Reino, J AU - BIOBADASER group TI - Survival of TNF antagonists in spondyloarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER J2 - Arthritis Res Ther PY - 2006 VL - 8 SP - R72 UR - https://doi.org/10.1186/ar1941 ER - TY - JOUR LB - 92. AU - Glintborg, B AU - Gudbjornsson, B AU - Krogh, NS AU - Omerovic, E AU - Manilo, N AU - Holland-Fischer, M TI - Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO J2 - Rheumatology PY - 2014 VL - 53 SP - 2100 EP - 2109 UR - https://doi.org/10.1093/rheumatology/keu252 ER - TY - JOUR LB - 93. AU - Iannone, F AU - Lopriore, S AU - Bucci, R AU - Scioscia, C AU - Anelli, MG AU - Notarnicola, A TI - Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA J2 - Scand J Rheumatol PY - 2015 VL - 44 SP - 192 EP - 199 UR - https://doi.org/10.3109/03009742.2014.962081 ER - TY - JOUR LB - 94. AU - Glintborg, B AU - Ostergaard, M AU - Krogh, NS AU - Andersen, MD AU - Tarp, U AU - Loft, AG TI - Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor inhibitor therapy: results from the Danish nationwide DANBIO registry J2 - Arthritis Rheum PY - 2013 VL - 65 SP - 1213 EP - 1223 UR - https://doi.org/10.1002/art.37876 ER - TY - JOUR LB - 95. AU - Fagerli, KM AU - Lie, E AU - van der Heijde, D AU - Heiberg, MS AU - Kalstad, S AU - Rødevand, E TI - Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study J2 - Ann Rheum Dis PY - 2013 VL - 72 SP - 1840 EP - 1844 UR - https://doi.org/10.1136/annrheumdis-2012-203018 ER - TY - JOUR LB - 96. AU - Eder, L AU - Thavaneswaran, A AU - Chandran, V AU - Gladman, DD TI - Tumour necrosis factor α blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis J2 - Ann Rheum Dis PY - 2014 VL - 73 SP - 1007 EP - 1011 UR - https://doi.org/10.1136/annrheumdis-2012-202959 ER - TY - JOUR LB - 97. AU - Saad, AA AU - Ashcroft, DM AU - Watson, KD AU - Symmons, DPM AU - Noyce, PR AU - Hyrich, KL TI - Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies J2 - Arthritis Care Res PY - 2010 VL - 62 SP - 345 EP - 353 UR - https://doi.org/10.1002/acr.20104 ER - TY - JOUR LB - 98. AU - Husted, JA AU - Tom, BD AU - Farewell, VT AU - Schentag, CT AU - Gladman, DD TI - Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach J2 - Arthritis Rheum PY - 2005 VL - 53 SP - 404 EP - 409 UR - https://doi.org/10.1002/art.21177 ER - TY - JOUR LB - 99. AU - Kane, D AU - Stafford, L AU - Bresnihan, B AU - Fitzgerald, O TI - A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience J2 - Rheumatology PY - 2003 VL - 42 SP - 1460 EP - 1468 UR - https://doi.org/10.1093/rheumatology/keg384 ER - TY - JOUR LB - 100. AU - Morgan, C AU - Lunt, M AU - Bunn, D AU - Scott, DG AU - Symmons, DP TI - Five-year outcome of a primary-care-based inception cohort of patients with inflammatory polyarthritis plus psoriasis J2 - Rheumatology PY - 2007 VL - 46 SP - 1819 EP - 1823 UR - https://doi.org/10.1093/rheumatology/kem270 ER - TY - JOUR LB - 101. AU - Mease, PJ AU - McInnes, IB AU - Gottlieb, AB AU - Widmer, A AU - Pricop, L AU - Mpofu, S TI - Secukinumab safety and tolerability in patients with active psoriatic arthritis and psoriasis: results from a pooled safety analysis J2 - Arthritis Rheumatol PY - 2015 VL - 67 IS - Suppl. S10 SP - 2886 ER - TY - JOUR LB - 102. AU - Singh, JA AU - Wells, GA AU - Christensen, R AU - Tanjong Ghogomu, E AU - Maxwell, L AU - Macdonald, JK TI - Adverse effects of biologics: a network meta-analysis and Cochrane overview J2 - Cochrane Database Syst Rev PY - 2011 VL - 2 SP - CD008794 UR - https://doi.org/10.1002/14651858.CD008794.pub2 ER - TY - JOUR LB - 103. AU - Askling, J AU - Fahrbach, K AU - Nordstrom, B AU - Ross, S AU - Schmid, CH AU - Symmons, D TI - Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data J2 - Pharmacoepidemiol Drug Saf PY - 2011 VL - 20 SP - 119 EP - 130 UR - https://doi.org/10.1002/pds.2046 ER - TY - JOUR LB - 104. AU - Corbett, M AU - Soares, M AU - Jhuti, G AU - Rice, S AU - Spackman, E AU - Sideris, E TI - Tumour necrosis factor-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation J2 - Health Technol Assess PY - 2016 VL - 20 IS - 9 UR - https://doi.org/10.3310/hta20090 ER - TY - JOUR LB - 105. AU - Tarp, S AU - Tarp, U AU - Andersen, LS AU - Lorenzen, T AU - Lindegaard, HM AU - Stoltenberg, M TI - Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel J2 - Arthritis Rheum PY - 2013 VL - 65 SP - S997 EP - S998 ER - TY - JOUR LB - 106. AU - Capogrosso-Sansone, A AU - Mantarro, S AU - Blandizzi, C AU - Montagnani, S AU - Ruggiero, E AU - Saporiti, A TI - Update of certolizumab pegol safety profile: a systematic review and meta-analysis J2 - Drug Saf PY - 2014 VL - 37 SP - 844 EP - 845 ER - TY - JOUR LB - 107. AU - Girolomoni, G AU - Altomare, G AU - Ayala, F AU - Berardesca, E AU - Calzavara-Pinton, P AU - Chimenti, S TI - Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis J2 - Immunopharmacol Immunotoxicol PY - 2012 VL - 34 SP - 548 EP - 560 UR - https://doi.org/10.3109/08923973.2011.653646 ER - TY - JOUR LB - 108. AU - Dixon, WG AU - Hyrich, KL AU - Watson, KD AU - Lunt, M TI - The influence of anti-TNF therapy upon the incidence and severity of serious lower respiratory tract infections in patients with rheumatoid arthritis: results from the BSR biologics register (BSRBR) J2 - Rheumatology PY - 2008 VL - 47 IS - Suppl. 2 SP - ii47 ER - TY - JOUR LB - 109. AU - Mariette, X AU - Tubach, F AU - Bagheri, H AU - Bardet, M AU - Berthelot, JM AU - Gaudin, P TI - Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry J2 - Ann Rheum Dis PY - 2010 VL - 69 SP - 400 EP - 408 UR - https://doi.org/10.1136/ard.2009.117762 ER - TY - JOUR LB - 110. AU - Zisman, D AU - Bitterman, H AU - Shalom, G AU - Feldhamer, I AU - Comanesther, D AU - Batat, E TI - Psoriatic arthritis treatment and the risk of herpes zoster J2 - Ann Rheum Dis PY - 2016 VL - 75 SP - 131 EP - 135 UR - https://doi.org/10.1136/annrheumdis-2013-205148 ER - TY - ELEC LB - 111. AU - Dias, S AU - Welton, NJ AU - Sutton, AJ AU - Ades, AE TI - NICE DSU Technical Support Document 1: Introduction to Evidence Synthesis for Decision Making PY - 2011 UR - http://scharr.dept.shef.ac.uk/nicedsu/technical-support-documents/evidence-synthesis-tsd-series/ ER - TY - BOOK LB - 112. AU - National Institute for Health and Care Excellence (NICE) TI - Multiple Technology Appraisal. Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis Following Inadequate Response to Disease Modifying Antirheumatic Drugs [ID579]. Final Scope CY - London PB - NICE PY - 2015 UR - www.nice.org.uk/guidance/GID-TAG521/documents/final-scope Y2 - 14 December 2016 ER - TY - JOUR LB - 113. AU - Julious, S AU - Wong, SJ TI - How biased are indirect comparisons, particularly when comparisons are made over time in controlled trials? J2 - Drug Inf J PY - 2008 VL - 42 SP - 625 EP - 633 UR - https://doi.org/10.1177/009286150804200610 ER - TY - ELEC LB - 114. AU - Dias, S AU - Sutton, AJ AU - Welton, NJ AU - Ades, AE TI - NICE DSU Technical Support Document 3: Heterogeneity: Subgroups, Meta-regression, Bias and Bias-adjustment PY - 2011 UR - http://scharr.dept.shef.ac.uk/nicedsu/technical-support-documents/evidence-synthesis-tsd-series/ M1 - December 2016 ER - TY - JOUR LB - 115. AU - Spiegelhalter, DJ AU - Best, NG AU - Carlin, BP AU - van der Linde, A TI - Bayesian measures of model complexity and fit (with discussion) J2 - J R Stat Soc Series B Stat Methodol PY - 2002 VL - 64 SP - 583 EP - 639 UR - https://doi.org/10.1111/1467-9868.00353 ER - TY - JOUR LB - 116. AU - Mease, PJ AU - Woolley, JM AU - Bitman, B AU - Wang, BC AU - Globe, DR AU - Singh, A TI - Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction J2 - J Rheumatol PY - 2011 VL - 38 SP - 2461 EP - 2465 UR - https://doi.org/10.3899/jrheum.110546 ER - TY - ELEC LB - 117. AU - Dias, S AU - Welton, NJ AU - Sutton, AJ AU - Ades, AE TI - NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-analysis of Randomised Controlled Trials PY - 2011 UR - http://scharr.dept.shef.ac.uk/nicedsu/technical-support-documents/evidence-synthesis-tsd-series/ M1 - December 2016 ER - TY - JOUR LB - 118. AU - Yang, H AU - Epstein, D AU - Bojke, L AU - Craig, D AU - Light, K AU - Bruce, I TI - Golimumab for the treatment of psoriatic arthritis J2 - Health Technol Assess PY - 2011 VL - 15 IS - Suppl. 1 UR - https://doi.org/10.3310/hta15suppl1/10 ER - TY - BOOK LB - 119. AU - Drummond, M AU - Sculpher, MJ AU - Torrance, GW AU - O’Brien, BJ AU - Stoddart, GL TI - Methods for the Economic Evaluation of Health Care Programmes ET - 3rd edn. CY - Oxford PB - Oxford University Press PY - 2005 ER - TY - JOUR LB - 120. AU - Codreanu, C AU - Mogosanu, C AU - Joita, M AU - Purcaru, O TI - Cost-effectiveness of certolizumab pegol in the treatment of active rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis in Romania J2 - Value Health PY - 2014 VL - 17 SP - A379 UR - https://doi.org/10.1016/j.jval.2014.08.2608 ER - TY - JOUR LB - 121. AU - Tzanetakos, C AU - Vassilopoulos, D AU - Kourlaba, G AU - Christou, P AU - Maniadakis, N TI - Cost–utility analysis of certolizumab pegol for the treatment of active psoriatic arthritis in Greece J2 - Value Health PY - 2015 VL - 18 SP - A646 EP - A647 UR - https://doi.org/10.1016/j.jval.2015.09.2319 ER - TY - JOUR LB - 122. AU - Bojke, L AU - Epstein, D AU - Craig, D AU - Rodgers, M AU - Woolacott, N AU - Yang, H TI - Modelling the cost-effectiveness of biologic treatments for psoriatic arthritis J2 - Rheumatology PY - 2011 VL - 50 IS - Suppl. 4 SP - 39 EP - 47 UR - https://doi.org/10.1093/rheumatology/ker245 ER - TY - JOUR LB - 123. AU - Einarson, TR AU - Bereza, BG AU - Bobro, I AU - Efremova, E AU - Lelli, F TI - Economic analysis of ustekinumab for psoriatic arthritis in Russia J2 - Value Health PY - 2015 VL - 18 SP - A648 UR - https://doi.org/10.1016/j.jval.2015.09.2325 ER - TY - JOUR LB - 124. AU - Wang, X AU - Bansback, N AU - Anis, A AU - Joshi, AD AU - Rao, S AU - Wolff, M TI - Economic evaluation model of biologic therapies for moderate to severe psoriatic arthritis in Germany J2 - Value Health PY - 2012 VL - 15 SP - A446 UR - https://doi.org/10.1016/j.jval.2012.08.1392 ER - TY - BOOK LB - 125. AU - National Institute for Health and Care Excellence TI - Guide to the Methods of Technology Appraisal 2013 CY - London PB - NICE PY - 2013 ER - TY - JOUR LB - 126. AU - Madan, J AU - Ades, T AU - Barton, P AU - Bojke, L AU - Choy, E AU - Helliwell, P TI - Consensus decision models for biologics in rheumatoid and psoriatic arthritis: recommendations of a multidisciplinary working party J2 - Rheumatol Ther PY - 2015 VL - 2 SP - 113 EP - 125 UR - https://doi.org/10.1007/s40744-015-0020-0 ER - TY - JOUR LB - 127. AU - Kyle, S AU - Chandler, D AU - Griffiths, CE AU - Helliwell, P AU - Lewis, J AU - McInnes, I TI - Guideline for anti-TNF-alpha therapy in psoriatic arthritis J2 - Rheumatology PY - 2005 VL - 44 SP - 390 EP - 397 UR - https://doi.org/10.1093/rheumatology/keh514 ER - TY - JOUR LB - 128. AU - Smith, CH AU - Anstey, AV AU - Barker, JN AU - Burden, AD AU - Chalmers, RJ AU - Chandler, DA TI - British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009 J2 - Br J Dermatol PY - 2009 VL - 161 SP - 987 EP - 1019 UR - https://doi.org/10.1111/j.1365-2133.2009.09505.x ER - TY - JOUR LB - 129. AU - Kobelt, G AU - Jönsson, L AU - Lindgren, P AU - Young, A AU - Eberhardt, K TI - Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis J2 - Arthritis Rheum PY - 2002 VL - 46 SP - 2310 EP - 2319 UR - https://doi.org/10.1002/art.10471 ER - TY - JOUR LB - 130. AU - Bansback, NJ AU - Ara, R AU - Barkham, N AU - Brennan, A AU - Fraser, AD AU - Conway, P TI - Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis J2 - Rheumatology PY - 2006 VL - 45 SP - 1029 EP - 1038 UR - https://doi.org/10.1093/rheumatology/kel147 ER - TY - JOUR LB - 131. AU - Hartman, M AU - Prins, M AU - Swinkels, OQ AU - Severens, JL AU - De Boo, T AU - Van Der Wilt, GJ TI - Cost-effectiveness analysis of a psoriasis care instruction programme with dithranol compared with UVB phototherapy and inpatient dithranol treatment J2 - Br J Dermatol PY - 2002 VL - 147 SP - 538 EP - 544 UR - https://doi.org/10.1046/j.1365-2133.2002.04920.x ER - TY - BOOK LB - 132. AU - National Institute for Health and Care Excellence TI - Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis CY - London PB - NICE PY - 2010 UR - www.nice.org.uk/guidance/ta199 Y2 - September 2017 ER - TY - JOUR LB - 133. AU - Cummins, E AU - Asseburg, C AU - Prasad, M AU - Buchanan, J AU - Punekar, YS TI - Cost effectiveness of golimumab for the treatment of active psoriatic arthritis J2 - Eur J Health Econ PY - 2012 VL - 13 SP - 801 EP - 809 UR - https://doi.org/10.1007/s10198-011-0335-x ER - TY - BOOK LB - 134. AU - Anon TI - Monthly Index of Medical Specialities (MIMS) CY - London PB - Haymarket Media Group Ltd PY - 2016 ER - TY - BOOK LB - 135. AU - Joint Formulary Committee TI - British National Formulary 2015 CY - London PB - BMJ Group and Pharmaceutical Press PY - 2015 ER - TY - BOOK LB - 136. AU - Curtis, L AU - Burns, A TI - Unit Costs of Health and Social Care 2015 CY - Canterbury PB - Personal Social Services Research Unit, University of Kent PY - 2015 ER - TY - BOOK LB - 137. AU - Department of Health (DH) TI - NHS Reference Costs 2014 to 2015 CY - London PB - DH PY - 2015 ER - TY - JOUR LB - 138. AU - Poole, CD AU - Lebmeier, M AU - Ara, R AU - Rafia, R AU - Currie, CJ TI - Estimation of health care costs as a function of disease severity in people with psoriatic arthritis in the UK J2 - Rheumatology PY - 2010 VL - 49 SP - 1949 EP - 1956 UR - https://doi.org/10.1093/rheumatology/keq182 ER - TY - BOOK LB - 139. AU - Joint Formulary Committee TI - British National Formulary CY - London PB - BMJ Group and Pharmaceutical Press PY - 2016 ER - TY - BOOK LB - 140. AU - National Institute for Health and Care Excellence TI - Etanercept, Infliximab and Adalimumab for the Treatment of Psoriatic Arthritis [TA199] CY - London PB - NICE PY - 2010 ER - TY - BOOK LB - 141. AU - Dolan, P AU - Gudex, C AU - Kind, P AU - Williams, A TI - A Social Tariff for EuroQol: Results from a UK General Population Survey. Centre for Health Economics Discussion Paper 138 CY - Centre for Health Economics, University of York PB - York PY - 1995 ER - TY - BOOK LB - 142. AU - Briggs, A AU - Sculpher, M AU - Claxton, K TI - Decision Modelling for Health Economic Evaluation CY - Oxford PB - Oxford University Press PY - 2006 ER - TY - JOUR LB - 143. AU - Asaria, M AU - Walker, S AU - Palmer, S AU - Gale, CP AU - Shah, AD AU - Abrams, KR TI - Using electronic health records to predict costs and outcomes in stable coronary artery disease J2 - Heart PY - 2016 VL - 102 SP - 755 EP - 762 UR - https://doi.org/10.1136/heartjnl-2015-308850 ER - TY - BOOK LB - 144. AU - HM Treasury TI - The Green Book: Appraisal and Evaluation in Central Government CY - London PB - HM Treasury PY - 2013 ER - TY - BOOK LB - 145. AU - Office for National Statistics TI - National Life Tables, UK: 2013–2015 CY - Newport PB - Office for National Statistics PY - 2015 ER - TY - JOUR LB - 146. AU - Poyner, TF AU - Wall, ARJ AU - Adnitt, PI AU - Menday, AP TI - Economic impact of psoriasis treatment on the patient and on the National Health Service J2 - J Dermatol Treatment PY - 1999 VL - 10 SP - 25 EP - 29 ER - TY - JOUR LB - 147. AU - Karlsson, G AU - Johannesson, M TI - The decision rules of cost-effectiveness analysis J2 - PharmacoEconomics PY - 1996 VL - 9 SP - 113 EP - 120 UR - https://doi.org/10.2165/00019053-199609020-00003 ER - TY - CHAP LB - 148. AU - Lefebvre, C AU - Manheimer, E AU - Glanville, J TI - Chapter 6: Searching for Studies A2 - Higgins, J A2 - Green, S T2 - Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (Updated March 2011) PB - The Cochrane Collaboration PY - 2011 UR - www.cochrane-handbook.org Y2 - December 2016 ER - TY - JOUR LB - 149. AU - Lefebvre, C AU - Eisinga, A AU - McDonald, S AU - Paul, N TI - Enhancing access to reports of clinical trials published world-wide – the contribution of EMBASE records to the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library J2 - Emerg Themes Epidemiol PY - 2008 VL - 5 SP - 13 UR - https://doi.org/10.1186/1742-7622-5-13 ER - TY - ELEC LB - 150. AU - Centre for Reviews and Dissemination TI - Search Strategies for DARE PY - 2015 UR - www.crd.york.ac.uk/crdweb/searchstrategies.asp M1 - 15 December 2015 ER - TY - JOUR LB - 151. AU - Langley, RG AU - Elewski, BE AU - Lebwohl, M AU - Reich, K AU - Griffiths, CE AU - Papp, K TI - Secukinumab in plaque psoriasis – results of two phase 3 trials J2 - N Engl J Med PY - 2014 VL - 371 SP - 326 EP - 338 UR - https://doi.org/10.1056/NEJMoa1314258 ER - TY - JOUR LB - 152. AU - Adams, R AU - Walsh, C AU - Veale, D AU - Bresnihan, B AU - FitzGerald, O AU - Barry, M TI - Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis J2 - PharmacoEconomics PY - 2010 VL - 28 SP - 477 EP - 487 UR - https://doi.org/10.2165/11533010-000000000-00000 ER - TY - JOUR LB - 153. AU - Adams, R AU - Craig, BM AU - Walsh, CD AU - Veale, DJ AU - Bresnihan, B AU - FitzGerald, O TI - The impact of a revised EQ-5D population scoring on preference-based utility scores in an inflammatory arthritis cohort J2 - Value Health PY - 2011 VL - 14 SP - 921 EP - 927 UR - https://doi.org/10.1016/j.jval.2011.03.002 ER - TY - JOUR LB - 154. AU - Brodszky, V AU - Péntek, M AU - Bálint, PV AU - Géher, P AU - Hajdu, O AU - Hodinka, L TI - Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a cross-sectional survey J2 - Scand J Rheumatol PY - 2010 VL - 39 SP - 303 EP - 309 UR - https://doi.org/10.3109/03009740903468982 ER - TY - JOUR LB - 155. AU - Gratacós, J AU - Daudén, E AU - Gómez-Reino, J AU - Moreno, JC AU - Casado, MÁ AU - Rodríguez-Valverde, V TI - Health-related quality of life in psoriatic arthritis patients in Spain J2 - Reumatol Clin PY - 2014 VL - 10 SP - 25 EP - 31 UR - https://doi.org/10.1016/j.reuma.2013.05.006 ER - TY - JOUR LB - 156. AU - Leung, YY AU - Png, ME AU - Wee, HL AU - Thumboo, J TI - Comparison of EuroQol-5D and short form-6D utility scores in multiethnic Asian patients with psoriatic arthritis: a cross-sectional study J2 - J Rheumatol PY - 2013 VL - 40 SP - 859 EP - 865 UR - https://doi.org/10.3899/jrheum.120782 ER - TY - JOUR LB - 157. AU - Picchianti-Diamanti, A AU - Germano, V AU - Ferlito, C AU - Migliore, A AU - D’Amelio, R AU - Lagana, B TI - Health-related quality of life and disability in patients with rheumatoid, early rheumatoid and early psoriatic arthritis treated with etanercept J2 - Qual Life Res PY - 2010 VL - 19 SP - 821 EP - 826 UR - https://doi.org/10.1007/s11136-010-9651-3 ER - TY - JOUR LB - 158. AU - Stolfa, J TI - Golimumab in the PsA treatment J2 - Rheumatologia PY - 2010 VL - 24 SP - 31 EP - 37 ER -